Antibodies targeting the protein Claudin18.2, as Flame’s FL-301 does, have been the focus of some biotechnology dealmaking over the past year, involving companies like Turning Point Therapeutics, Elevation Oncology and even AstraZeneca.
Claudin18.2 is expressed in gastrointestinal and pancreatic cancers, making it a relevant target for would-be treatments.
Flame acquired its Claudin18.2-targeting drug candidate through an agreement in 2021 with the cancer and autoimmune disease-focused biotech NovaRock Biotherapeutics.
